These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 653643)

  • 1. Lithium inhibition of ristocetin-induced fibrinogen precipitation.
    Hayes PC; Hargreaves LN
    Thromb Res; 1978 Mar; 12(3):567-8. PubMed ID: 653643
    [No Abstract]   [Full Text] [Related]  

  • 2. The influence of Haemaccel, fibrinogen and albumin on ristocetin-induced platelet aggregation. Relevance to the quantitative measurement of the ristocetin cofactor.
    Stibbe J; Kirby EP
    Thromb Res; 1976 Feb; 8(2):151-65. PubMed ID: 1251347
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of ADP and ATP on bovine fibrinogen- and ristocetin-induced platelet aggregation in Glanzmann's thrombasthenia.
    Cohen I; Glaser T; Seligsohn U
    Br J Haematol; 1975 Nov; 31(3):343-7. PubMed ID: 1201247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proceedings: Inhibition of ristocetin-induced platelet aggregation (RIPA) by Haemaccel and fibrinogen.
    Stibbe J; Kirby E
    Thromb Diath Haemorrh; 1975 Nov; 34(2):583. PubMed ID: 1198487
    [No Abstract]   [Full Text] [Related]  

  • 5. Plasma components which interfere with ristocetin-induced platelet aggregation.
    Baugh RF; Brown JE; Hougie C
    Thromb Diath Haemorrh; 1975 Jun; 33(3):540-6. PubMed ID: 1080300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of lithium and calcium ions on the aggregation of human blood platelets.
    Hargreaves LN; Hayes PC
    Thromb Res; 1978 Jul; 13(1):79-83. PubMed ID: 694836
    [No Abstract]   [Full Text] [Related]  

  • 7. Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy.
    Borawski J; Rydzewski A; Mazerska M; Kalinowski M; Pawlak K; Mysliwiec M
    Nephrol Dial Transplant; 1996 Dec; 11(12):2444-8. PubMed ID: 9017620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of receptors for fibrinogen and von Willebrand factor mediating aggregation in guinea pig platelets.
    Kupinski JM; Miller JL
    Thromb Res; 1986 Aug; 43(3):335-44. PubMed ID: 3016944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some factors affecting fibrinogen precipitation by ristocetin: ultrastructure of precipitates.
    Ts'ao C; Green D; Rossi EC
    Blood; 1975 May; 45(5):621-9. PubMed ID: 1120188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precipitation of fibrin monomers and fibrin degradation products by ristocetin.
    Watanabe K; Tullis JL
    Am J Med Sci; 1978; 275(3):337-44. PubMed ID: 80134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Willebrand factor and ristocetin. I. Mechanism of rustocetin-induced platelet aggregation.
    Jenkins CS; Meyer D; Dreyfus MD; Larrieu MJ
    Br J Haematol; 1974 Dec; 28(4):561-78. PubMed ID: 4141901
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter: Heparin and ristocetin-reduced platelet aggregation.
    Pekcelen Y; Inceman S
    Br Med J; 1975 Oct; 4(5988):101-2. PubMed ID: 1182460
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative studies of available ristocetins: proteolytic activity and effect on platelets.
    Jenkins CS; Meyer D; Ardaillou N; Lombard C; Larrieu MJ
    Thromb Res; 1975 Oct; 7(4):531-42. PubMed ID: 1081758
    [No Abstract]   [Full Text] [Related]  

  • 14. Inhibition of ristocetin-induced platelet agglutination by vancomycin.
    Moake JL; Cimo PL; Peterson DM; Roper P; Natelson EA
    Blood; 1977 Sep; 50(3):397-406. PubMed ID: 301760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the characterization of acquired inhibitors to ristocetin induced platelet aggregation found in patients with von Willebrand's disease.
    Egberg N; Blombäck M
    Thromb Res; 1976 Nov; 9(5):527-31. PubMed ID: 1087055
    [No Abstract]   [Full Text] [Related]  

  • 16. Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation.
    De Marco L; Girolami A; Zimmerman TS; Ruggeri ZM
    Proc Natl Acad Sci U S A; 1985 Nov; 82(21):7424-8. PubMed ID: 2932740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proceedings: Drug inhibition of ristocetin-induced platelet aggregation.
    Tann G; Flute PT
    Thromb Diath Haemorrh; 1975 Sep; 34(1):340-1. PubMed ID: 1188776
    [No Abstract]   [Full Text] [Related]  

  • 18. Further studies of the interaction between ristocetin and fibrinogen.
    Goh AT; Firkin BG
    Haemostasis; 1976; 5(2):57-65. PubMed ID: 950175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of vancomycin on ristocetin and bovine PAF-induced agglutination of human platelets.
    Baugh RF; Jacoby C; Brown JE; Hougie C
    Thromb Res; 1978 Mar; 12(3):511-21. PubMed ID: 306689
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunoinhibition of ristocetin-induced platelet aggregation.
    Nachman RL; Jaffe EA; Weksler BB
    J Clin Invest; 1977 Jan; 59(1):143-8. PubMed ID: 299747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.